63590-64-7 Category:
  • #LGM Pharma is a Terazosin CAS# 63590-64-7 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, delivery, purity, and more.
  • #Questions? Call our customer API support number 1-(800)-881-8210.
  • #LGM Pharma offers this active ingredient but not the finished dosage forms.

Product Details:

  • CAS No: 63590-64-7
  • AHFC code: 24:20.0
  • Synonyms: Abbott 45975 Terazosin HCl Terazosin hydrochloride Terazosina [INN-Spanish] Terazosine Terazosine [INN-French] Terazosinum [INN-Latin] Trazosin HCl
  • ATC Code: G04CA03
  • Chemical Formula: C32H41NO2
  • Molecular Weight: 387.4329
  • Assay/Purity: Typically NLT 98%
  • DrugBank: DB01162 (APRD00667)
  • PubChem: 5401
  • IUPAC: 6,7-dimethoxy-2-{4-[(oxolan-2-yl)carbonyl]piperazin-1-yl}quinazolin-4-amine

Additional Details

For the treatment of symptomatic BPH and mild to moderate hypertension.
Terazosin, classified as a quinazoline, is similar to doxazosin and prazosin. As an _-adrenergic blocking agent, terazosin is used to treat hypertension and BPH. Terazosin produces vasodilation and reduces peripheral resistance but in general has only a slight effect on cardiac output. The antihypertensive effect with chronic dosing is not usually accompanied by reflex tachycardia.
Mode of Action:
In general, __-adrenergic receptors mediate contraction and hypertrophic growth of smooth muscle cells. __-Receptors are 7-transmembrane domain receptors coupled to G proteins, Gq/__. Three __-receptor subtypes, which share approximately 75% homology in their transmembrane domains, have been identified: __A (chromosome 8), __B (chromosome 5), and __D (chromosome _0). Terazosin is the first __-receptor antagonist to demonstrate selectivity for the __A-receptor. All three receptor subtypes appear to be involved in maintaining vascular tone. The __A-receptor maintains basal vascular tone while the __B-receptor mediates the vasocontrictory effects of exogenous __-agonists. Activation of __-receptors activates Gq-proteins, which results in intracellular stimulation of phospholipases C, A_, and D. This results in mobilization of Ca_+ from intracellular stores, activation of mitogen-activated kinase and PI_ kinase pathways and subsequent vasoconstriction. Terozosin produces its pharmacological effects by inhibiting __A-receptor activation. Inhibition of these receptors in the vasculature and prostate results in muscle relaxation, decreased blood pressure and improved urinary outflow in symptomatic benign prostatic hyperplasia.
Hepatic. One of the four metabolites identified (piperazine derivative of terazosin) has antihypertensive activity.
LD50=259.3mg/kg (IV in mice)
General Reference:
Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, Black HR, Hamilton BP, Holland J, Nwachuku C, Papademetriou V, Probstfield J, Wright JT Jr, Alderman MH, Weiss RJ, Piller L, Bettencourt J, Walsh SM: Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002 Nov-Dec;4(6):393-404. Pubmed
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Cost effective materials based on specific requirements
  • Small quantities for initial research and larger development quantities towards product commercialization


  • Technical packages, letters of access to filed DMFs
  • Complete assistance in any regulatory filings
  • Top quality GMP certified manufacturers
  • Have necessary regulatory credentials


Related YouTube Videos